Aurora Cannabis Gets a Buy Rating from Canaccord Genuity

Aurora Cannabis (TSXV: ACB), the Materials sector company, has received a rating update from a Wall Street analyst today. Analyst Neil Maruoka from Canaccord Genuity rated Aurora Cannabis (TSXV: ACB) a Buy, setting a C$11 price target.

Maruoka has an average return of 5.8% when recommending Aurora Cannabis.

According to TipRanks.com, Maruoka is ranked #1465 out of 4787 analysts.

Aurora Cannabis has an analyst consensus of Moderate Buy, with a price target consensus of C$11.

Aurora Cannabis, Inc. engages in the provision of medical cannabis. Its activities include cultivating, harvesting, and selling of Canadian medical marijuana. It operates through the Production and Sale of Medical Cannabis; and Patient Counselling and Outreach Services.

The company’s shares closed on Tuesday at C$7.78.